GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Immunotherapy for Endometrial Cancer: Which Test Results Affect Your Options?

For U.S. primary advanced or recurrent endometrial cancer, deficient mismatch repair (dMMR) is required for durvalumab with chemotherapy; the pembrolizumab and dostarlimab chemotherapy combinations do not require dMMR. [1][2][3] After progression on systemic treatment, MSI-high (MSI-H) or dMMR can meet the tumor-test condition for pembrolizumab alone, while mismatch-repair proficient (pMMR) or not MSI-H can meet it for pembrolizumab with lenvatinib. Both indications also require that curative surgery or radiation is not an option. [4][5] Dostarlimab alone has a separate dMMR, post-platinum indication. [6] HER2, POLE, p53 and ER/PR do not by themselves establish eligibility for these regimens. [1][2][3][4][5][6]

Which result should I ask for?

Ask for the tumor’s mismatch-repair (MMR) immunohistochemistry (IHC) report and any microsatellite-instability (MSI) test result. A missing result is not evidence of pMMR disease. The pembrolizumab label reports discordance between local MSI-H/dMMR findings and central tests in a KEYNOTE-158 cohort; it does not establish that every MMR and MSI assay is interchangeable. If results conflict or cannot be read, ask your pathology team whether the sample or tests need review before a treatment decision. [4]

Immunotherapy for Endometrial Cancer: Which Test Results Affect Your Options?

Does MMR matter with initial chemotherapy?

In KEYNOTE-868/NRG-GY018, 222 patients were in the dMMR cohort and 588 were in the pMMR cohort. Median progression-free survival—time until cancer worsened or a patient died—was not reached versus 6.5 months in dMMR, and 11.1 versus 8.5 months in pMMR, for pembrolizumab plus carboplatin and paclitaxel versus placebo plus the same chemotherapy. “Not reached” means the median could not yet be calculated at that analysis. The trial did not compare checkpoint drugs with each other. Patients with prior adjuvant chemotherapy entered only after a chemotherapy-free interval of at least 12 months. [4]

What changes after prior treatment?

The U.S. pembrolizumab-alone and pembrolizumab–lenvatinib indications specify an FDA-authorized tumor test; the FDA notice for dostarlimab alone specifies an FDA-approved test. The test must establish the relevant MSI-H/dMMR or pMMR/not MSI-H condition. It cannot, on its own, establish treatment history or whether curative surgery or radiation is an option. [4][5][6]

KEYNOTE-775/Study 309 enrolled 827 patients previously treated with platinum chemotherapy. In its 697-person pMMR/not MSI-H efficacy group, median overall survival was 17.4 months with pembrolizumab–lenvatinib versus 12.0 months with doxorubicin or paclitaxel. The trial did not test whether this regimen works as a second checkpoint treatment after prior PD-1 or PD-L1 therapy. [4][5]

Dostarlimab alone requires dMMR recurrent or advanced disease after progression on or following a platinum-containing regimen, with no option for curative surgery or radiation. This is a different indication from dostarlimab given with chemotherapy and then continued alone for primary advanced or recurrent disease. [2][6]

Does a high TMB score change the answer?

Only under a separate, tumor-agnostic U.S. accelerated-approval indication: the 2026 pembrolizumab label specifies tumor mutational burden (TMB) of at least 10 mutations per megabase on an FDA-authorized test for unresectable or metastatic solid tumors that progressed after treatment and have no satisfactory alternative. [4] In the FDA’s supporting analysis, 29% of 102 people with TMB-high tumors of different cancer types responded; this is not an endometrial-cancer-specific rate. [7] A POLE finding cannot substitute for the measured TMB or MMR/MSI results required by the relevant U.S. indications. [4]

Which results answer a different question?

HER2 may inform discussion of HER2-targeted treatment for HER2-positive uterine serous cancer; it does not select a checkpoint drug in the cited trastuzumab study. [8] POLE and p53 findings in the postoperative PORTEC-3 analysis inform risk and adjuvant-treatment discussions, not checkpoint selection. [9] ER and PR findings may inform hormone-treatment discussions, but the cited GOG studies did not test immunotherapy choices. [10][11]

What should I take to my oncologist?

Bring the MMR IHC and any MSI report, the cancer stage, and dates of prior systemic, platinum and checkpoint treatments. If available, bring the measured TMB result. Ask your oncologist which tested result and prior treatment match the proposed regimen, and whether curative local treatment remains an option. For administrative help preparing records or requesting an appointment in Japan, JPNSTEMCELL describes its records and appointment-coordination role; its medical-records policy explains handling when you authorize sharing. Neither service interprets pathology or offers an anticancer drug.

Checkpoint drugs can cause serious inflammation in the lungs, bowel, liver or hormone-producing glands; lenvatinib also requires blood-pressure monitoring. [4][5] Contact your treatment team urgently for new shortness of breath or persistent or severe diarrhea, and seek emergency care for severe symptoms. A U.S. FDA indication does not establish Japanese approval, coverage or availability; check with your treating oncology team before making treatment decisions. Do not change prescribed treatment because of this article.

Editorial note: This article has not received article-specific physician review. It cannot replace advice from your treating oncology team. The site’s medical disclaimer explains the limits of its information and coordination services.

Need help organizing your records or requesting an appointment in Japan? Contact the coordination team →

Primary sources

  1. [1] U.S. FDA, pembrolizumab plus chemotherapy approval and NRG-GY018 (2024).
  2. [2] U.S. FDA, dostarlimab plus chemotherapy expanded indication (2024).
  3. [3] U.S. FDA, dMMR durvalumab plus chemotherapy indication (2024).
  4. [4] U.S. FDA, KEYTRUDA U.S. prescribing information, §§1.17–1.18, 14.8, 14.17–14.18 (2026).
  5. [5] U.S. FDA, LENVIMA U.S. prescribing information, §§1.4, 5.1, 14.4 (2026).
  6. [6] U.S. FDA, dostarlimab monotherapy dMMR approval (2023).
  7. [7] U.S. FDA, TMB-high pembrolizumab accelerated approval (2020).
  8. [8] Fader et al., HER2-positive uterine serous randomized phase II trial, Clinical Cancer Research (2020).
  9. [9] León-Castillo et al., PORTEC-3 molecular analysis, Journal of Clinical Oncology (2020).
  10. [10] Singh et al., GOG 119 original study abstract (PMID 17532033), Gynecologic Oncology (2007).
  11. [11] Thigpen et al., GOG medroxyprogesterone dose-response original study abstract (PMID 10561210), Journal of Clinical Oncology (1999).
Reviewed by GINZA Medical Coordination Team

Content is prepared for patient education and international consultation planning. It does not replace an individual diagnosis by a licensed physician.